Predictors of pathological stage before neoadjuvant androgen withdrawal therapy and radical prostatectomy

Journal of Urology

Volumn 159, Issue 3, 1998, Pages 925-928

  Rabbani, Farhang ^a   Goldenberg, S Larry ^a   Klotz, Laurence H ^a   Sullivan, L D ^a   Gleave, M E ^a   McLoughlin, M G ^a   Prestage, K ^a   Kinahan, T J ^a   Orovan, W L ^a   Whelan, J P ^a   Srigley, J ^a   Jewett, M A S ^a   Herschorn, S ^a   Keresteci, A G ^a   Robinette, M ^a   Bruce, A ^a   Chin, J ^a   Stewart, D A ^a   Ruether, J D ^a   Ernst, D S ^a   Mador, D ^a   Chetner, M ^a   Metcalfe, J B ^a   Fradet, Y ^a   Paquin, J M ^a   Elhilali, M ^a   Aprikian, A G ^a   Bertrand, P E ^a   Schick, E ^a   Tessier, J ^a   Halsall, A K ^a   Weckworth, P F ^a   more..

^a NONE

Author keywords

Hormones; Pathology; Prostatectomy; Prostatic neoplasms

Indexed keywords

CYPROTERONE ACETATE; PROSTATE SPECIFIC ANTIGEN;

ARTICLE; CANCER HORMONE THERAPY; CANCER STAGING; CANCER SURGERY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG WITHDRAWAL; HUMAN; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; RANDOMIZED CONTROLLED TRIAL; STATISTICAL ANALYSIS; TUMOR BIOPSY;

EID: 6844252281     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-5347(01)63772-8     Document Type: Article

References (24)

1. Goldenberg, S. L., Klotz, L. H., Srigley, J., Jewett, M. A. S., Mador, D., Fradet, Y., Barkin, J., Chin, J., Faquin, J. -M., Bullock, M. J. and LaPlante, S. and Canadian Urologic Oncology Group: Randomized, prospective, controlled study comparing radical prostatectomy alone and neoadjuvant androgen withdrawal in the treatment of localized prostate cancer. J. Urol., 156: 873, 1996.
2. Fair, W. R., Aprikian, A. G., Cohen, D., Sogani, P. and Reuter, V.: Use of neoadjuvant androgen deprivation therapy in clinically localized prostate cancer. Clin. Invest. Med., 16: 516, 1993.
3. Soloway, M. S., Sharifi, R., Wajsman, Z., McLeod, D., Wood, D. P., Jr. and Puras-Baez, A. for the Lupron Depot Neoadjuvant Prostate Cancer Study Group: Randomized prospective study comparing radical prostatectomy alone versus radical prostatectomy preceded by androgen blockade in clinical stage B2 (T2bNxM0) prostate cancer. J. Urol., 154: 424, 1995.
4. van Poppel, H., de Ridder, D., Elgamal, A. A., van de Voorde, W., Werbrouck, P., Ackaert, K., Oyen, R., Pittomvils, G. and Baert, L. and members of the Belgian Uro-Oncological Study Group: Neoadjuvant hormonal therapy before radical prostatectomy decreases the number of positive surgical margins in stage T2 prostate cancer: interim results of a prospective randomized trial. J. Urol., 154: 429, 1995.
5. Gleave, M. E., Goldenberg, S. L., Jones, E. C., Bruchovsky, N. and Sullivan, L. D.: Biochemical and pathological effects of 8 months of neoadjuvant androgen withdrawal therapy before radical prostatectomy in patients with clinically confined prostate cancer. J. Urol., 155: 213, 1996.
6. Abbas, F. and Scardino, P. Y.: Why neoadjuvant androgen deprivation therapy prior to radical prostatectomy is unnecessary. Urol. Clin. N. Amer., 23: 587, 1996.
7. Rabbani, F., Sullivan, L. D., Goldenberg, S. L. and Stothers, L.: Neoadjuvant androgen deprivation therapy before radical prostatectomy: who is unlikely to benefit? Brit. J. Urol., 79: 221, 1997.
8. Partin, A. W., Yoo, J., Carter, H. B., Pearson, J. D., Chan, D. W., Epstein, J. I. and Walsh, P. C.: The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer. J. Urol., 150: 110, 1993.
9. Narayan, P., Gajendran, V., Taylor, S. P., Tewari, A., Presti, J. C., Jr., Leidich, R., Lo, R., Palmer, K., Shinohara, K. and Spaulding, J. T.: The role of transrectal ultrasound-guided biopsy-based staging, preoperative serum prostate-specific antigen, and biopsy Gleason score in prediction of final pathologic diagnosis in prostate cancer. Urology, 46: 205, 1995.
10. Kleer, E., Larson-Keller, J. J., Zincke, H. and Oesterling, J. E.: Ability of preoperative serum prostate-specific antigen value to predict pathologic stage and DNA ploidy: influence of clinical stage and tumor grade. Urology, 41: 207, 1993.
11. Epstein, J. I., Partin, A. W., Sauvageot, J. and Walsh, P. C.: Prediction of progression following radical prostatectomy: a multivariate analysis of 721 men with long-term follow-up. Amer. J. Surg. Path., 20: 286, 1996.
12. Ohori, M., Wheeler, T. M., Kattan, M. W., Goto, Y. and Scardino, P. T.: Prognostic significance of positive surgical margins in radical prostatectomy specimens. J. Urol., 154: 1818, 1995.
13. Weldon, V. E., Tavel, F. R., Neuwirth, H. and Cohen, R.: Patterns of positive specimen margins and detectable prostate specific antigen after radical perineal prostatectomy. J. Urol., 153: 1565, 1995.
14. Labrie, F., Dupont, A., Cusan, L., Gomez, J., Diamond, P., Koutsilieris, M., Suburu, R., Fradet, Y., Lemay, M., Têtu, B., Emond, J. and Candas, B.: Downstaging of localized prostate cancer by neoadjuvant therapy with flutamide and lupron: the first controlled and randomized trial. Clin. Invest. Med., 16: 499, 1993.
15. Epstein, J. I.: Incidence and significance of positive margins in radical prostatectomy specimens. Urol. Clin. N. Amer., 23: 651, 1996.
16. Partin, A. W., Carter, H. B., Chan, D. W., Epstein, J. I., Oesterling, J. E., Rock, R. C., Weber, J. P. and Walsh, P. C.: Prostate specific antigen in the staging of localized prostate cancer: influence of tumor differentiation, tumor volume and benign hyperplasia. J. Urol., 143: 747, 1990.
17. Stamey, T. A., Villers, A. A., McNeal, J. E., Link, P. C. and Freiha, F. S.: Positive surgical margins at radical prostatectomy: importance of the apical dissection. J. Urol., 143: 1166, 1990.
18. Ackerman, D. A., Barry, J. M., Wicklund, R. A., Olson, N. and Lowe, B. A.: Analysis of risk factors associated with prostate cancer extension to the surgical margin and pelvic node metastasis at radical prostatectomy. J. Urol., 150: 1845, 1993.
19. Optenberg, S., Thompson, I. M., Friedrichs, P. A., Moul, J., Klein, E. and Crawford, E. D.: Development of a model for the prediction of extraprostatic (pT3) disease in carcinoma of the prostate (PC): highest risk in the hispanic male - no impact of neoadjuvant hormonal therapy (NHT). J. Urol., part 2, 157: 297A, abstract 1158, 1997.
20. Kattan, M. W., Stapleton, A. M. F., Wheeler, T. M. and Scardino, P. T.: Evaluation of a nomogram used to predict the pathologic stage of clinically localized prostate carcinoma. Cancer, 79: 528, 1997.
21. Aprikian, A. G., Fair, W. R., Reuter, V. E., Sogani, P., Herr, H., Russo, P. and Sheinfeld, J.: Experience with neoadjuvant diethylstilboestrol and radical prostatectomy in patients with locally advanced prostate cancer. Brit. J. Urol., 74: 630, 1994.
22. Voges, G. E., Mottrie, A. M., Fichtner, J., Mappes, C., Störkel, S., Stöckle, M. and Hohenfellner, R.: Maximum androgen deprivation prior to radical retropubic prostatectomy in patients with stage T3 adenocarcinoma of the prostate. Eur. Urol., 28: 209, 1995.
23. Cher, M. L., Shinohara, K., Breslin, S., Vapnek, J. and Carroll, P. R.: High failure rate associated with long-term follow-up of neoadjuvant androgen deprivation followed by radical prostatectomy for stage C prostatic cancer. Brit. J. Urol., 75: 771, 1995.
24. Bostwick, D. G., Qian, J., Bergstralh, E., Dundore, P., Dugan, J., Myers, R. P. and Oesterling, J. E.: Prediction of capsular perforation and seminal vesicle invasion in prostate cancer. J. Urol., 155: 1361, 1996.